Rociletinib
Appearance
![]() | |
Clinical data | |
---|---|
Other names | CO-1686, AVL-301 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H28F3N7O3 |
Molar mass | 555.562 g·mol−1 |
3D model (JSmol) | |
| |
|
Rociletinib (INN) is a drug for the treatment of non-small cell lung cancer, acting as an inhibitor of the epidermal growth factor receptor (EGFR).[1] It was being developed by Clovis Oncology.[2] According to the company web site as of November 2016, development was halted and studies on the drug are no longer accepting new patients, but Clovis will continue to supply the drug to patients whose physicians had recommended continued treatment.[3]
References
- ^ Van Der Steen, Nele; Caparello, Chiara; Rolfo, Christian; Pauwels, Patrick; Peters, Godefridus; Giovannetti, Elisa (2016). "New developments in the management of non-small-cell lung cancer, focus on rociletinib: What went wrong?". OncoTargets and Therapy. 9: 6065. doi:10.2147/OTT.S97644. PMC 5063481. PMID 27785053.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.
- ^ "About Clovis". Retrieved 18 November 2016.